<DOC>
	<DOCNO>NCT02125461</DOCNO>
	<brief_summary>A Global Study Assess Effects MEDI4736 follow concurrent chemoradiation Patients Stage III Unresectable Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>A Global Study Assess Effects MEDI4736 Following Concurrent Chemoradiation Patients With Stage III Unresectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>A Phase III , Randomised , Double-blind , Placebo-controlled , Multi-centre , International Study MEDI4736 Sequential Therapy Patients Locally Advanced , Unresectable Non-Small Cell Lung Cancer ( Stage III ) Who Have Not Progressed Following Definitive , Platinum-based , Concurrent Chemoradiation Therapy ( PACIFIC )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age least 18 year . 2 . Documented evidence NSCLC ( locally advance , unresectable , Stage III ) 3 . Patients must receive least 2 cycle platinumbased chemotherapy concurrent radiation therapy . 4 . World Health Organisation ( WHO ) Performance Status 0 1 . 5 . Estimated life expectancy 12 week . 1 . Prior exposure antiPD1 antiPDL1 antibody . 2 . Active prior autoimmune disease history immunodeficiency . 3 . Evidence severe uncontrolled systemic disease , include active bleeding diatheses active infection include hepatitis B , C HIV . 4 . Evidence uncontrolled illness symptomatic congestive heart failure , uncontrolled hypertension unstable angina pectoris . 5 . Any unresolved toxicity CTCAE &gt; Grade 2 prior chemoradiation therapy . 6 . Active prior document inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>Unresectable Non-Small Cell Lung Cancer</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>PD-L1</keyword>
	<keyword>Stage III Non-Small Cell Lung Cancer</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Immune-mediated cancer therapy</keyword>
</DOC>